Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.

Compared with placebo, 20 mg rimonabant led to statistically significant increases in HDL-C (+22.3% vs +13.4%; p < 0.001) and decreases in total cholesterol to HDL-C ratio, triglycerides (−6.8% vs +8.3%; p < 0.0001), fasting glucose, fasting insulin, and insulin resistance (measured by the homeostasis model assessment [HOMA]); effects with 5 mg rimonabant did not reach statistical significance compared with placebo except in HDL-C (+16.2% vs +13.4%; p = 0.048).

also in 111,027 other papers